Ardelyx Inc (NASDAQ: ARDX) has filed a lawsuit against the U.S. Department of Health and Human Services and the Centers for Medicare and Medicaid Services over the inclusion of its kidney disease treatment drug, Xphozah, in the Medicare payment bundle system. The company argues that this decision will limit patient access to crucial medications. The lawsuit highlights broader concerns within the pharmaceutical industry regarding regulatory decisions impacting drug accessibility and patient care standards.